Dicloxacillin is an inducer of intestinal P‐glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users
Dicloxacillin increases expression of intestinal P-gp, leading to reduced oral absorption of dabigatran. However, concomitant use of dicloxacillin/flucloxacillin was not associated with stroke and systemic embolism among DOAC users, suggesting no clinical impact from the drug-drug interaction between dicloxacillin/flucloxacillin and DOACs.
Authors
- Ditte B. Iversen (ORCID: https://orcid.org/0000-0002-5519-9091)
- Tore Bjerregaard Stage (ORCID: https://orcid.org/0000-0002-4698-4389)
- Ann‐Cathrine Dalgård Dunvald (ORCID: https://orcid.org/0000-0001-7574-0909)
- Olaf H. Klungel (ORCID: https://orcid.org/0000-0002-5604-813X)
- Helen Hammer (ORCID: https://orcid.org/0000-0001-8187-0240)
- Flemming Nielsen (ORCID: https://orcid.org/0000-0002-5657-405X)
- Per Damkier (ORCID: https://orcid.org/0000-0003-0591-7187)
- Martin Ernst (ORCID: https://orcid.org/0000-0001-9003-3823)
- Erkka Järvinen (ORCID: https://orcid.org/0000-0001-8970-5194)
- Shahab Abtahi (ORCID: https://orcid.org/0000-0003-0482-5563)
- Anton Pottegård (ORCID: https://orcid.org/0000-0001-9314-5679)
- Patrick Cyriel Souverein (ORCID: https://orcid.org/0000-0002-7452-0477)
- Kim Brøsen (ORCID: https://orcid.org/0000-0001-8444-7835)
- Glenn Brøde Jeppesen
- Oliver Pötz
Institutions
- University of Southern Denmark (DK)
- Utrecht University (NL)
- Odense University Hospital (DK)
- Natural and Medical Sciences Institute (DE)
- Signatope GmbH (Germany)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1111/bcp.16190
- Citations
- 3
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.21
Funders
- Lundbeckfonden
- Novo Nordisk
- Odense Universitetshospital
- Novo Nordisk Fonden
- H. Lundbeck A/S